Potential role of 18F-DOPA PET in neuroblastoma

Arnoldo Piccardo, Egesta Lopci

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

18F-3,4-Dihydroxyphenylalanine (DOPA) is the radio-labelled analogue of DOPA, a precursor of dopamine and catecholamines. It is a multivalent molecule that is widely used for functional imaging of various neural crest tumors, documenting a better diagnostic accuracy compared to 123I-metaiodobenzylguanidine (123I-mIBG) scintigraphy and other conventional imaging modalities. Neuroblastoma (NB) is an embryonic tumor deriving from the peripheral sympathetic nervous system, commonly included into the vast group of neural crest tumors. So, it maintains the ability to produce and release biologically active amines and in most cases is characterized by an increased metabolism of catecholamines. 123I-mIBG scintigraphy represents a “cornerstone” in the assessment of NB at initial diagnosis, (re)staging and treatment response evaluation. Nevertheless this modality presents several drawbacks, thus leading the necessity to find “new” tools for the assessment of NB. 18F-DOPA is probably the most promising PET alternative to 123I-MIBG in NB and published data, although apparently limited, seem to support this hypothesis. For the current review we have performed a revision of the literature to find relevant published articles concerning the diagnostic and clinical significance of 18F-DOPA PET in the evaluation of patients with NB.

Original languageEnglish
Pages (from-to)79-86
Number of pages8
JournalClinical and Translational Imaging
Volume4
Issue number2
DOIs
Publication statusPublished - Apr 1 2016

Fingerprint

Dihydroxyphenylalanine
Neuroblastoma
Radionuclide Imaging
Catecholamines
3-Iodobenzylguanidine
Sympathetic Nervous System
Peripheral Nervous System
Radio
Amines
Dopamine
Neoplasms

Keywords

  • Diagnosis
  • F-DOPA PET
  • Neuroblastoma
  • Prognosis
  • Response to therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Potential role of 18F-DOPA PET in neuroblastoma. / Piccardo, Arnoldo; Lopci, Egesta.

In: Clinical and Translational Imaging, Vol. 4, No. 2, 01.04.2016, p. 79-86.

Research output: Contribution to journalArticle

@article{1481892561dd44a0bd99fd407e721c0d,
title = "Potential role of 18F-DOPA PET in neuroblastoma",
abstract = "18F-3,4-Dihydroxyphenylalanine (DOPA) is the radio-labelled analogue of DOPA, a precursor of dopamine and catecholamines. It is a multivalent molecule that is widely used for functional imaging of various neural crest tumors, documenting a better diagnostic accuracy compared to 123I-metaiodobenzylguanidine (123I-mIBG) scintigraphy and other conventional imaging modalities. Neuroblastoma (NB) is an embryonic tumor deriving from the peripheral sympathetic nervous system, commonly included into the vast group of neural crest tumors. So, it maintains the ability to produce and release biologically active amines and in most cases is characterized by an increased metabolism of catecholamines. 123I-mIBG scintigraphy represents a “cornerstone” in the assessment of NB at initial diagnosis, (re)staging and treatment response evaluation. Nevertheless this modality presents several drawbacks, thus leading the necessity to find “new” tools for the assessment of NB. 18F-DOPA is probably the most promising PET alternative to 123I-MIBG in NB and published data, although apparently limited, seem to support this hypothesis. For the current review we have performed a revision of the literature to find relevant published articles concerning the diagnostic and clinical significance of 18F-DOPA PET in the evaluation of patients with NB.",
keywords = "Diagnosis, F-DOPA PET, Neuroblastoma, Prognosis, Response to therapy",
author = "Arnoldo Piccardo and Egesta Lopci",
year = "2016",
month = "4",
day = "1",
doi = "10.1007/s40336-016-0162-2",
language = "English",
volume = "4",
pages = "79--86",
journal = "Clinical and Translational Imaging",
issn = "2281-5872",
publisher = "Springer-Verlag Italia s.r.l.",
number = "2",

}

TY - JOUR

T1 - Potential role of 18F-DOPA PET in neuroblastoma

AU - Piccardo, Arnoldo

AU - Lopci, Egesta

PY - 2016/4/1

Y1 - 2016/4/1

N2 - 18F-3,4-Dihydroxyphenylalanine (DOPA) is the radio-labelled analogue of DOPA, a precursor of dopamine and catecholamines. It is a multivalent molecule that is widely used for functional imaging of various neural crest tumors, documenting a better diagnostic accuracy compared to 123I-metaiodobenzylguanidine (123I-mIBG) scintigraphy and other conventional imaging modalities. Neuroblastoma (NB) is an embryonic tumor deriving from the peripheral sympathetic nervous system, commonly included into the vast group of neural crest tumors. So, it maintains the ability to produce and release biologically active amines and in most cases is characterized by an increased metabolism of catecholamines. 123I-mIBG scintigraphy represents a “cornerstone” in the assessment of NB at initial diagnosis, (re)staging and treatment response evaluation. Nevertheless this modality presents several drawbacks, thus leading the necessity to find “new” tools for the assessment of NB. 18F-DOPA is probably the most promising PET alternative to 123I-MIBG in NB and published data, although apparently limited, seem to support this hypothesis. For the current review we have performed a revision of the literature to find relevant published articles concerning the diagnostic and clinical significance of 18F-DOPA PET in the evaluation of patients with NB.

AB - 18F-3,4-Dihydroxyphenylalanine (DOPA) is the radio-labelled analogue of DOPA, a precursor of dopamine and catecholamines. It is a multivalent molecule that is widely used for functional imaging of various neural crest tumors, documenting a better diagnostic accuracy compared to 123I-metaiodobenzylguanidine (123I-mIBG) scintigraphy and other conventional imaging modalities. Neuroblastoma (NB) is an embryonic tumor deriving from the peripheral sympathetic nervous system, commonly included into the vast group of neural crest tumors. So, it maintains the ability to produce and release biologically active amines and in most cases is characterized by an increased metabolism of catecholamines. 123I-mIBG scintigraphy represents a “cornerstone” in the assessment of NB at initial diagnosis, (re)staging and treatment response evaluation. Nevertheless this modality presents several drawbacks, thus leading the necessity to find “new” tools for the assessment of NB. 18F-DOPA is probably the most promising PET alternative to 123I-MIBG in NB and published data, although apparently limited, seem to support this hypothesis. For the current review we have performed a revision of the literature to find relevant published articles concerning the diagnostic and clinical significance of 18F-DOPA PET in the evaluation of patients with NB.

KW - Diagnosis

KW - F-DOPA PET

KW - Neuroblastoma

KW - Prognosis

KW - Response to therapy

UR - http://www.scopus.com/inward/record.url?scp=84967143983&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84967143983&partnerID=8YFLogxK

U2 - 10.1007/s40336-016-0162-2

DO - 10.1007/s40336-016-0162-2

M3 - Article

AN - SCOPUS:84967143983

VL - 4

SP - 79

EP - 86

JO - Clinical and Translational Imaging

JF - Clinical and Translational Imaging

SN - 2281-5872

IS - 2

ER -